Melanoma
News and reporting on melanoma.
Immatics Prices $150M Stock Offering
The firm plans to use the proceeds to advance its pipeline of T-cell receptor therapies and support their manufacturing, production, and commercialization.
The firm is gearing up for a registration-directed trial based on a positive Phase Ib readout and after discussions with US and German health authorities.
Immatics to Raise $150M in Public Stock Offering
The firm is developing T-cell receptor therapies for advanced solid tumors including metastatic melanoma.
UK Consortium Launches With Public-Private Funding to ID Immunotherapy Biomarkers
The Francis Crick Institute and the Royal Marsden Foundation Trust are spearheading the MANIFEST project with £21.9 million in government and industry funding.
Achilles Therapeutics Shuts Down Engineered Cell Therapy Program, Explores Cost-Cutting Measures
The firm is discontinuing its CHIRON and THETIS trials after lackluster data and is planning for potential third-party deals and workforce layoffs.